Charles Shyng, Ph.D.

Charles Shyng is a Preclinical Research Lead/Manager at Spark Therapeutics, Inc., where he focuses on developing gene therapies for rare diseases. He holds a Ph.D. in Molecular Cell Biology from Washington University in St. Louis and has over a decade of research experience in genetic medicines and rare diseases, particularly in AAV (adeno-associated virus) gene therapy.

Professional Background

• Current Role: Preclinical Research Lead at Spark Therapeutics, where he is involved in advancing AAV gene therapy programs.
• Previous Experience: He has worked as a Principal Scientist at Pfizer's BioMedicine Design unit, contributing significantly to the development of AAV gene therapy for lysosomal storage disorders. His career began with research positions at Washington University School of Medicine and included roles as a T32 Postdoctoral Research Trainee at the University of North Carolina at Chapel Hill and as a Scientific Consultant at Ostrea Bio, Inc..3

Education

• Bachelor's Degree: Biology with a focus on Neuroscience from Washington University in St. Louis.
• Doctorate: Ph.D. in Molecular Cell Biology from the same institution.

Contributions and Interests

Shyng is recognized for his work in capsid discovery and evaluation for AAV production, which is crucial for in vivo studies. He is also an advocate for rare diseases and emphasizes teamwork and leadership within his research endeavors.13

His LinkedIn profile indicates that he remains open to new opportunities within the field of genetic medicine, particularly those that involve advancements in treatments for rare diseases.12